Candel Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst on December 5. Analyst Alec Stranahan from Bank of America Securities maintained a Hold rating on the stock and has a $7.00 price target.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Alec Stranahan’s rating is based on the progress and challenges Candel Therapeutics faces in its development programs. The company has shown promising results with its CAN-2409 treatment for prostate cancer and non-small cell lung cancer (NSCLC), but the path to regulatory approval and market uptake remains a critical factor. The recent R&D day highlighted the importance of physician sentiment and regulatory pathways, which will be crucial as the company moves towards later-stage trials and potential approval.
While the data for CAN-2409 appears solid, especially with an 85% probability of success in their model, the company still faces hurdles in terms of financing and market penetration. The upcoming BLA submission for prostate cancer and the initiation of a pivotal trial for NSCLC are key milestones. Additionally, the early data for CAN-3110 in recurrent high-grade glioma (rHGG) is promising, but further long-term data is needed to assess its potential. These factors contribute to the Hold rating, reflecting a balanced view of the company’s potential and the risks involved.
CADL’s price has also changed slightly for the past six months – from $5.550 to $5.330, which is a -3.96% drop .